Besonprodil (CI-1041) is a drug which acts as an
NMDA antagonist, selective for the
NR2B subunit.[1][2] It is under development as a supplemental medication for
Parkinson's disease, and has been shown in animals to be effective in counteracting the
dyskinesias associated with long-term treatment with
levodopa and related drugs.[3][4][5][6][7]
References
^Kovács G, Kocsis P, Tarnawa I, Horváth C, Szombathelyi Z, Farkas S (January 2004). "NR2B containing NMDA receptor dependent windup of single spinal neurons". Neuropharmacology. 46 (1): 23–30.
doi:
10.1016/S0028-3908(03)00339-3.
PMID14654094.
S2CID20562296.
^Barton ME, White HS (March 2004). "The effect of CGX-1007 and CI-1041, novel NMDA receptor antagonists, on kindling acquisition and expression". Epilepsy Research. 59 (1): 1–12.
doi:
10.1016/j.eplepsyres.2003.12.010.
PMID15135162.
S2CID23859984.
^Morissette M, Dridi M, Calon F, Hadj Tahar A, Meltzer LT, Bédard PJ, Di Paolo T (January 2006). "Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin". Movement Disorders. 21 (1): 9–17.
doi:
10.1002/mds.20654.
PMID16127720.
S2CID34794881.
^Morissette M, Dridi M, Calon F, Hadj Tahar A, Meltzer LT, Bédard PJ, Di Paolo T (September 2006). "Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors". Synapse (New York, N.Y.). 60 (3): 239–50.
doi:
10.1002/syn.20295.
PMID16739115.
S2CID28098042.
^Ouattara B, Belkhir S, Morissette M, Dridi M, Samadi P, Grégoire L, Meltzer LT, Di Paolo T (June 2009). "Implication of NMDA receptors in the antidyskinetic activity of cabergoline, CI-1041, and Ro 61-8048 in MPTP monkeys with levodopa-induced dyskinesias". Journal of Molecular Neuroscience. 38 (2): 128–42.
doi:
10.1007/s12031-008-9137-8.
PMID18704766.
S2CID22646602.
^Ouattara B, Hoyer D, Grégoire L, Morissette M, Gasparini F, Gomez-Mancilla B, Di Paolo T (June 2010). "Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias". Neuroscience. 167 (4): 1160–7.
doi:
10.1016/j.neuroscience.2010.03.022.
PMID20303391.
S2CID40680667.